MRD levels in subsets of patients defined according to prognostic factors
| Patient categories . | MRD level (%)* . | P . |
|---|---|---|
| Cytogenetics | ||
| Favorable (n = 49) | 0.26 ± 0.33 (0.09) | |
| Intermediate (n = 28) | 0.8 ± 1.1 (0.30) | .05 |
| Adverse (n = 7) | 1.2 ± 1.6 (0.68) | |
| Number cycles to CR | ||
| One (n = 101) | 0.42 ± 0.75 (0.19) | .02 |
| Two (n = 25) | 1.05 ± 1.26 (0.56) | |
| WBC (× 109/L) | ||
| Less than 50 × 109 (n = 107) | 0.47 ± 0.74 (0.2) | .01 |
| Greater than 50 × 109 (n = 18) | 1.02 ± 1.49 (0.41) |
| Patient categories . | MRD level (%)* . | P . |
|---|---|---|
| Cytogenetics | ||
| Favorable (n = 49) | 0.26 ± 0.33 (0.09) | |
| Intermediate (n = 28) | 0.8 ± 1.1 (0.30) | .05 |
| Adverse (n = 7) | 1.2 ± 1.6 (0.68) | |
| Number cycles to CR | ||
| One (n = 101) | 0.42 ± 0.75 (0.19) | .02 |
| Two (n = 25) | 1.05 ± 1.26 (0.56) | |
| WBC (× 109/L) | ||
| Less than 50 × 109 (n = 107) | 0.47 ± 0.74 (0.2) | .01 |
| Greater than 50 × 109 (n = 18) | 1.02 ± 1.49 (0.41) |
Mean ± SD (median).